Flipper, the 1100 - 1500 prices from 2002 are the adjusted prices resulting from 2 reverse splits over the years: a 1-for-15 in 2007 and a 1-for-16 in 2012. Dividing 1100-1500 by 240 (15*16) yields prices back in the day of 4.5 - 6.25, about right for a new biotech. Don't know where 17100 came from; have not seen it on any site or service.
The company clearly has had a difficult history, which is why I think many institutions want to see beyond the Phase I data to get on board. But difficult histories are not unique in biotech - if you look at the long term charts of many companies, you see a common pattern of steady decline for many years while trials are being run and regular capital raises dilute shareholders until the treatment is proven or disproven; if proven, then the pattern reverses.
All that matters now is the look forward, and for me, NWBO is worth the risk that the inflection point is not far away. If and when it happens, the institutions that have stayed away will come back big given the eventual market of all solid cancers, boosting the gains accordingly.
News 
Market Data 
Discover 
